Jinyu Bio-technology Past Earnings Performance
Past criteria checks 1/6
Jinyu Bio-technology's earnings have been declining at an average annual rate of -6.2%, while the Biotechs industry saw earnings growing at 5.9% annually. Revenues have been growing at an average rate of 3.1% per year. Jinyu Bio-technology's return on equity is 2.9%, and it has net margins of 12.2%.
Key information
-6.2%
Earnings growth rate
-5.7%
EPS growth rate
| Biotechs Industry Growth | 11.3% |
| Revenue growth rate | 3.1% |
| Return on equity | 2.9% |
| Net Margin | 12.2% |
| Next Earnings Update | 28 Nov 2024 |
Recent past performance updates
Recent updates
The Consensus EPS Estimates For Jinyu Bio-technology Co., Ltd. (SHSE:600201) Just Fell Dramatically
Sep 04
Revenue Miss: Jinyu Bio-technology Co., Ltd. Fell 9.1% Short Of Analyst Revenue Estimates And Analysts Have Been Revising Their Models
Sep 02Why We're Not Concerned Yet About Jinyu Bio-technology Co., Ltd.'s (SHSE:600201) 25% Share Price Plunge
Jun 16Jinyu Bio-technology Co., Ltd. (SHSE:600201) Analysts Are Reducing Their Forecasts For This Year
Apr 30There's Reason For Concern Over Jinyu Bio-technology Co., Ltd.'s (SHSE:600201) Price
Mar 21Does This Valuation Of Jinyu Bio-technology Co., Ltd. (SHSE:600201) Imply Investors Are Overpaying?
Feb 28Revenue & Expenses Breakdown
How Jinyu Bio-technology makes and spends money. Based on latest reported earnings, on an LTM basis.
Earnings and Revenue History
| Date | Revenue | Earnings | G+A Expenses | R&D Expenses |
|---|---|---|---|---|
| 30 Sep 24 | 1,350 | 165 | 471 | 122 |
| 30 Jun 24 | 1,525 | 272 | 479 | 137 |
| 31 Mar 24 | 1,582 | 283 | 510 | 149 |
| 31 Dec 23 | 1,598 | 284 | 518 | 143 |
| 30 Sep 23 | 1,639 | 289 | 475 | 155 |
| 30 Jun 23 | 1,572 | 240 | 461 | 145 |
| 31 Mar 23 | 1,551 | 236 | 436 | 133 |
| 31 Dec 22 | 1,529 | 211 | 423 | 134 |
| 30 Sep 22 | 1,546 | 174 | 461 | 158 |
| 30 Jun 22 | 1,578 | 229 | 462 | 161 |
| 31 Mar 22 | 1,599 | 252 | 487 | 164 |
| 31 Dec 21 | 1,776 | 382 | 503 | 166 |
| 30 Sep 21 | 1,813 | 529 | 456 | 142 |
| 30 Jun 21 | 1,798 | 482 | 454 | 138 |
| 31 Mar 21 | 1,735 | 467 | 418 | 137 |
| 31 Dec 20 | 1,582 | 406 | 399 | 131 |
| 30 Sep 20 | 1,387 | 268 | 399 | 111 |
| 30 Jun 20 | 1,240 | 234 | 357 | 96 |
| 31 Mar 20 | 1,159 | 213 | 355 | 90 |
| 31 Dec 19 | 1,127 | 221 | 345 | 87 |
| 30 Sep 19 | 1,312 | 322 | 377 | 91 |
| 30 Jun 19 | 1,646 | 565 | 389 | 107 |
| 31 Mar 19 | 1,673 | 617 | 395 | 111 |
| 31 Dec 18 | 1,897 | 754 | 413 | 107 |
| 30 Sep 18 | 2,008 | 869 | 502 | 106 |
| 30 Jun 18 | 1,909 | 842 | 476 | 114 |
| 31 Mar 18 | 1,997 | 900 | 469 | 87 |
| 31 Dec 17 | 1,901 | 870 | 448 | 72 |
| 30 Sep 17 | 1,809 | 842 | 396 | 42 |
| 30 Jun 17 | 1,651 | 748 | 413 | 0 |
| 31 Mar 17 | 1,635 | 719 | 424 | 0 |
| 31 Dec 16 | 1,517 | 645 | 415 | 0 |
| 30 Sep 16 | 1,393 | 561 | 377 | 0 |
| 30 Jun 16 | 1,309 | 518 | 363 | 0 |
| 31 Mar 16 | 1,252 | 505 | 356 | 0 |
| 31 Dec 15 | 1,247 | 480 | 356 | 0 |
| 30 Sep 15 | 1,210 | 499 | 328 | 0 |
| 30 Jun 15 | 1,116 | 436 | 330 | 0 |
| 31 Mar 15 | 1,063 | 433 | 297 | 0 |
| 31 Dec 14 | 1,063 | 404 | 311 | 0 |
| 30 Sep 14 | 921 | 346 | 278 | 0 |
| 30 Jun 14 | 874 | 308 | 250 | 0 |
| 31 Mar 14 | 849 | 277 | 231 | 0 |
| 31 Dec 13 | 671 | 251 | 220 | 0 |
Quality Earnings: 600201 has high quality earnings.
Growing Profit Margin: 600201's current net profit margins (12.2%) are lower than last year (17.6%).
Free Cash Flow vs Earnings Analysis
Past Earnings Growth Analysis
Earnings Trend: 600201's earnings have declined by 6.2% per year over the past 5 years.
Accelerating Growth: 600201's has had negative earnings growth over the past year, so it can't be compared to its 5-year average.
Earnings vs Industry: 600201 had negative earnings growth (-42.9%) over the past year, making it difficult to compare to the Biotechs industry average (0.08%).
Return on Equity
High ROE: 600201's Return on Equity (2.9%) is considered low.